Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

Recovery of a 10-year-old girl from methicillin-resistant Staphylococcus aureus sepsis in response to low-dose ceftaroline treatment

Authors Borgmann S, Rieß B, von Wernitz-Keibel T, Matthias Buehler M, Layer F, Strommenger B

Received 6 November 2015

Accepted for publication 29 January 2016

Published 11 May 2016 Volume 2016:12 Pages 749—753


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Video abstract presented by Borgmann et al.

Views: 963

Stefan Borgmann,1 Beate Rieß,1 Thomas von Wernitz-Keibel,2 Matthias Bühler,3 Franziska Layer,4 Birgit Strommenger4

1Department of Infectious Diseases and Infection Control, 2Department of Anaesthesiology and Intensive Care Medicine, 3Department of Trauma Surgery, Klinikum Ingolstadt, Ingolstadt, 4National Reference Centre for Staphylococci and Enterococci, Division Nosocomial Pathogens and Antibiotic Resistances, Department for Infectious Diseases, Robert Koch Institute, Wernigerode Branch, Wernigerode, Germany

Abstract: A 9-year-old girl was severely injured in a car accident in Afghanistan, in which both her lower legs were badly damaged. She was treated at the Hospital of Ingolstadt (Klinikum Ingolstadt) after she had undergone initial surgery at an Indian hospital. Various bacterial species were isolated from multiple wounds, and methicillin-resistant Staphylococcus aureus (MRSA) was one among them. After the amputation of her lower legs, she developed MRSA sepsis, which was successfully treated with a relatively low dosage of ceftaroline (Zinforo®/Teflaro®; 2×9 mg/kg/d), although the bacterial isolate’s minimal inhibitory concentration (1.5–4 mg/L) suggested a decreased susceptibility. In summary, ceftaroline was highly efficient and well tolerated by the patient suffering from MRSA sepsis.

Keywords: side effects, susceptibility, ceftaroline, minimal inhibitory concentration, therapy 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]